Request Your Free White Paper Now:

"Beyond cfDNA: Harnessing the Power of Exosomes to Improve Sensitivity for Cancer Mutation Detection"

An Assessment of Four Peer Reviewed Articles

Despite considerable advances in molecular profiling, there remains a high unmet medical need for early cancer detection. Through a series of recent landmark FDA approvals, liquid biopsies, non-invasive mechanisms that allow for the characterization of disease from a freely accessible biofluid, are now making inroads in mainstream diagnostics.

Liquid biopsies are a rich source of biomarkers, such as circulating tumor cells (CTC), cell free DNA (cfDNA) and extracellular vesicles containing exosomal RNA (exoRNA). Significant advantages of liquid biopsies include their ability to be collected often without inconveniencing or harming the patient; samples can be collected from the point of diagnosis and throughout the course of disease to assess overall prognosis, response to therapy, and likelihood of relapse or progression; and they are less costly to perform than a tissue biopsy.

The analysis of cfDNA presents new opportunities to detect cancer early, distinguish cancer from benign conditions, and to identify fast- and slow-growing cancers. ExoRNA has also proven to be a useful source for detecting tumor-derived mutations. This insightful whitepaper summarizes four peer-reviewed articles that explore the combination of exoRNA and cfDNA in cancer diagnosis and treatment. Access now to learn more.

Offered Free by: Bio-Techne
See All Resources from: Bio-Techne